Cloud-Connected Automated Intravenous (IV) Compounding Market Report 2026

The cloud-connected automated intravenous (IV) compounding market size has grown rapidly in recent years. It will grow from $2.34 billion in 2025 to $2.73 billion in 2026 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to increasing adoption of automated IV compounding systems, growing demand for medication safety and accuracy, rising hospital investments in pharmacy automation, expansion of oncology and specialized treatment centers, and growing awareness of sterile compounding standards.

The cloud-connected automated intravenous (IV) compounding market size is expected to see rapid growth in the next few years. It will grow to $5.03 billion in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to increasing integration of cloud-based monitoring solutions, growing development of AI-powered error detection systems, rising investment in compact and modular robotic designs, expansion of homecare and decentralized pharmacy applications, and growing focus on interoperability and data analytics platforms. Major trends in the forecast period include technology advancement in cloud-connected workflow management, innovation in AI and machine learning for predictive compounding, development of smart consumables and sensors, research and development in oncology-specific automation solutions, and investment in scalable and remote monitoring deployment models.

The growing demand for biosimilars is anticipated to drive the expansion of the cloud-connected automated IV compounding sector in the coming years. Biosimilars are biologic medical products that are highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or efficacy. The increase in demand for biosimilars is primarily due to their cost-effectiveness compared to branded biologics. Automated IV compounding supports the safe and accurate preparation of biosimilars by minimizing human error, ensuring precise dosing, and preserving product integrity. For example, in January 2023, Cardinal Health Inc., a US-based healthcare company, reported that as of January 2022, the U.S. had 33 FDA-approved biosimilar products, with 21 available on the market, and by 2023, this number had risen to 40 FDA-approved biosimilars, with 25 commercially available. Consequently, the rising demand for biosimilars is fueling the growth of the cloud-connected automated IV compounding sector.

Leading companies in the cloud-connected automated intravenous (IV) compounding sector are prioritizing the enhancement of automated systems, including cloud-enabled monitoring and compliance tracking, to boost sterile preparation accuracy, minimize medication errors, and reinforce regulatory compliance. Cloud-enabled monitoring and compliance tracking involves integrated software and hardware solutions that enable healthcare facilities to access real-time data on IV compounding processes, maintain electronic audit trails, and ensure adherence to sterility and quality standards across multiple locations. For example, in May 2025, the United States Food and Drug Administration (FDA), a US-based regulatory authority, highlighted updated guidance and enforcement measures under section 503B of the Federal Food, Drug, and Cosmetic Act, mandating outsourcing facilities to uphold strict quality control and documentation for compounded sterile products. These regulations promote the adoption of automated IV compounding systems with cloud-based monitoring, electronic record-keeping, and remote quality oversight features.

In October 2025, Omnicell Inc., a US-based provider of healthcare automation and medication management systems, acquired ANiGENT LLC for an undisclosed amount. Through this acquisition, Omnicell intends to enhance its cloud-enabled medication management platform by incorporating advanced drug diversion detection and intelligence capabilities, thereby reinforcing its connected automation solutions, including cloud-connected IV compounding workflows. ANiGENT LLC is a US-based firm specializing in cloud-connected automated intravenous (IV) compounding solutions.

Major companies operating in the cloud-connected automated intravenous (iv) compounding market are McKesson Corporation, Becton Dickinson and Company, Baxter International Inc., B. Braun Melsungen SE, Fresenius Kabi AG, Grifols S.A., ICU Medical Inc., Syntegon Technology GmbH, Omnicell Inc., Marchesini Group S.p.A., Swisslog Healthcare, ScriptPro LLC, Parata Systems LLC, ARxIUM Inc., Equashield LLC, Health Robotics S.r.l., Rommelag AG, NewIcon Oy, DoseEdge, Aesynt Inc.

North America was the largest region in the cloud-connected automated intravenous (IV) compounding market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cloud-connected automated intravenous (iv) compounding market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cloud-connected automated intravenous (iv) compounding market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have impacted the cloud-connected automated iv compounding market by increasing costs for imported robotic systems, software, and consumables. the rise in production and import costs has particularly affected robotic compounding system manufacturers and software solution providers in regions like north america and europe. hospital pharmacies and oncology centers relying on imported equipment are most affected. however, tariffs are also encouraging local production and innovation, potentially improving cost optimization and supply chain resilience in the long term.

Cloud-connected automated intravenous (IV) compounding is a technology-enabled method that employs robotics and digital systems to prepare intravenous medications with exceptional precision. It incorporates cloud connectivity to allow real-time monitoring, data management, and ongoing performance optimization. By merging automation with intelligent remote functionalities, it improves safety, accuracy, and operational efficiency.

The key product types of cloud-connected automated IV compounding include robotic compounding systems, software solutions, and consumables. Robotic compounding systems are automated machines with cloud connectivity that prepare intravenous medications with high precision while enabling remote monitoring, data management, and workflow optimization. These systems may be deployed as cloud-hosted, hybrid cloud, or on-premises with cloud integration. Applications span hospital pharmacies, oncology centers, homecare settings, and others, with end users including hospitals, clinics, ambulatory surgical centers, and others.

The cloud-connected automated intravenous (IV) compounding market includes revenues earned by entities by providing services such as remote monitoring and support, workflow optimization services, cloud data management, system integration services, and predictive maintenance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cloud-connected automated IV compounding market consists of sales of automated IV compounding robots, cloud-connected workstations, sterile compounding isolators, IV workflow software platforms, and medication preparation sensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.